https://www.selleckchem.com/pr....oducts/telacebec-q20
be not necessary. In contrast, the aged surface could significantly decrease the SBS; hence subtractive surface treatments are highly recommended. The JO25567 randomized Phase II study demonstrated a statistically significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with erlotinib monotherapy in chemotherapy-naïve Japanese patients with epidermal growth factor receptor mutation-positive (EGFR+) non-small-cell lung cancer (NSCLC). Here we present updated PFS and final overall survival (OS) d
Like
Comment
Share
